RNA, U6 small nuclear 1022, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-1022P profile across patient tissues and cancer cell-line models. RNU6-1022P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RNU6-1022P is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, RNU6-1022P RNA expression shows 7,840 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, COAD, and PDAC as cancer lineages where RNU6-1022P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-1022P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-1022P survival associations across molecular data types. RNU6-1022P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-1022P RNA expression–survival associations across cancer types. High RNU6-1022P expression shows unfavorable associations in SKCM, TGCT, LAML, COAD and PAAD, but favorable associations in ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RNU6-1022P RNA expression.
This table summarizes RNU6-1022P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-1022P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-1022P shows lower tumor expression in COAD. The COAD box plot shows higher RNU6-1022P RNA expression in normal versus tumor tissue (log2 FC = −0.150, t-test p = .046).
This table shows molecular features associated with RNU6-1022P in patient tissues and cancer cell lines. In patient samples, RNU6-1022P shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
